A Phase 2/3 study of TQ-A3334 in Chronic HBV Infection
Active, Not Recruiting Phase 2 NCT06706310
Study Description
Evaluating the Safety and Efficacy of TQ-A3334, a Nucleoside (Acid) Analog, in the Treatment of Chronic Hepatitis B Virus Infection
Study Details
- Registry ID:
- NCT06706310
- Conditions:
- Chronic Hepatitis B
- Phase:
- Phase 2
- Target Enrollment:
- 116 participants
- Start Date:
- Age Range:
- 18–65 years
- Healthy Volunteers:
- No
Study Locations (18 sites)
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China -
Pu'er People's Hospital
Pu'er, Yunnan, China -
First People's Hospital of Yunnan Province
Kunming, Yunnan, China -
West China Hospital of Sichuan University
Chengdu, Sichuan, China -
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing, China -
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China -
Hospital workers in Liuzhou
Liuchow, Guangxi, China -
Hospital workers in Liuzhou
Liuzhou, Guangxi, China -
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, China -
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China -
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China -
The Second XIANGYA Hospital Of Central South University
Changsha, Hunan, China -
WuHan Jinyintan Hospital
WuHan, Hubei, China -
People's Hospital Of RuiAn City
Rui'an, Zhejiang, China -
People's Hospital Of RuiAn City
Rui’an, Zhejiang, China -
The Fifth People's Hospital of Wuxi (Affiliated Wuxi Fifth Hospital of Jiangnan University)
Wuxi, Jiangsu, China -
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China -
The first hospital of Jilin University
Changchun, Jilin, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.